Search bioRxivSearch

Biology subjects

Ho Leung Ng

Publications and source records attributed to Ho Leung Ng.

2 recordsLinked to original sources

Locating the ligand binding sites for the G-protein coupled estrogen receptor (GPER) using combined information from docking and sequence conservation

High concentrations of estrogenic compounds can overstimulate estrogen receptors and potentially lead to breast, ovarian, and cervical cancers. Recently, a G-protein coupled estrogen receptor (GPER/GPR30) was discovered that has no structural similarity to the well-characterized, classical estrogen receptor ER. The crystal structure of GPER has not yet been determined, and the ligand binding sites have not yet been experimentally identified. The recent explosion of GPCR crystal structures now allow homology modeling with unprecedented reliability. We create, validate, and describe a homology model for GPER. We describe and apply ConDock, the first hybrid scoring function to use information from protein surface conservation and ligand docking, to predict binding sites on GPER for four ligands, estradiol, G1, G15, and tamoxifen. ConDock is a simple product function of sequence conservation and binding energy scores. ConDock predicts that all four ligands bind to the same location on GPER, centered on L119, H307, and N310; this site is deeper in the receptor cleft than are ligand binding sites predicted by previous studies. We compare the sites predicted by ConDock and traditional methods analyzing surface geometry, surface conservation, and ligand chemical interactions. Incorporating sequence conservation information in ConDock avoids errors resulting from physics-based scoring functions and modeling.

Bioinformatics

Simulations reveal increased fluctuations in estrogen receptor-alpha conformation upon antagonist binding

Molecular dynamics (MD) simulations have been used to model dynamic fluctuations in the structure of estrogen receptor-alpha (ER-) upon binding to the natural agonist 17{beta}-estradiol (E2) and to the active metabolite of the breast cancer drug and antagonist, 4-hydroxytamoxifen (OHT). We present the most extensive MD simulations to date of ER-; with over 1 s of combined simulations for the monomer and dimer forms. Simulations reveal that the antagonist-bound complex includes significant fluctuations while the agonist-bound complex is tightly restrained. OHT increases dynamic disorder in the loops located to either side of the tail H12 helix; H12 has been associated with the activation status of ER-. We also report that fluctuations near H12 lead to greater conformational variation in the binding mode of the ethylamine tail of OHT. Both the agonist and antagonist conformations are stable throughout the 240 ns simulations, supporting the hypothesis that there are no transitions between these two states or into intermediate states. The stable position of H12 in the OHT-bound conformation suggests that OHT stabilizes a well-defined antagonist conformational ensemble rather than merely blocking the agonist-driven activation of ER-. Simultaneously, the increased dynamic properties of the OHT-bound complex is a potential source of binding entropy.

Bioinformatics